pharma · Diabetic Kidney Disease · ZVSA
ZyVersa Therapeutics
ZyVersa Therapeutics is a pharma organization headquartered in Weston, USA. It trades on NYSE under ticker ZVSA. Primary therapeutic focus areas include Diabetic Kidney Disease. NovaPharmaNews links 1 clinical program(s)
Weston, USA HQ
2014 Founded
11 Employees
Public company Type
ZVSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Weston, USA
- Founded
- 2014
- Employees
- 11
- Programs
- 1
- Drugs
- 0
- Patents
- 0
2HPβCD
Phase 2 · small molecule · Diabetic Kidney Disease
2HPβCD for Diabetic Kidney Disease is a Phase 2 program (small_molecule) at ZyVersa Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code VAR200-0301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ZyVersa Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diabetic Kidney Disease
- Status
- terminated
- Trials
- 1